Oncology Diagnostics
… Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a report published on Friday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for …
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold | Daily Political | 11/1/2020
Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR …
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Hold - Ticker Report | 11/1/2020
Biocept (NASDAQ:BIOC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR …
Biocept (NASDAQ:BIOC) Cut to “Hold” at Zacks Investment Research | 10/31/2020
… Investment Research cut shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research report released on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for …
Biocept (NASDAQ:BIOC) Upgraded to Buy by Zacks Investment Research - WKRB News | 10/30/2020
upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report issued on Monday morning, Zacks.com reports. currently has $5.00 price objective on the medical research company’s stock. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide …
… objective on the medical research company’s stock. Zacks Investment Research ‘s price objective would suggest a potential upside of 12.87% from the company’s previous close. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for …
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to Hold - WKRB News | 10/27/2020
Zacks Investment Research downgraded shares of Biocept (NASDAQ:BIOC) from a buy rating to a hold rating in a research note issued to investors on Friday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE …
Biocept (NASDAQ:BIOC) Upgraded to “Buy” at Zacks Investment Research - Ticker Report | 10/27/2020
upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $5.00 target price on the medical research company’s stock. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to …
… cells 2.2 Adaptive immune system 2.2.1 Lymphocytes 2.2.2 Killer T cells 2.2.3 Helper T cells 2.2.4 Gamma delta T cells 2.2.5 B lymphocytes and antibodies 2.3 Tumor immunology - the immune surveillance system 2.4 Immuno Oncology Diagnostics 2.4.1 Checkpoint Assays 2.4.2 Cytokine Assays 2.4.3 Genomic Germline 2.4.4 Genomic Tumour 2.4.5 Tumor Microenvironment 2.4.6 Others 2.4.6.1 Outlook for Other Diagnostics
- Industry Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research …
… cells 2.2 Adaptive immune system 2.2.1 Lymphocytes 2.2.2 Killer T cells 2.2.3 Helper T cells 2.2.4 Gamma delta T cells 2.2.5 B lymphocytes and antibodies 2.3 Tumor immunology - the immune surveillance system 2.4 Immuno Oncology Diagnostics 2.4.1 Checkpoint Assays 2.4.2 Cytokine Assays 2.4.3 Genomic Germline 2.4.4 Genomic Tumour 2.4.5 Tumor Microenvironment 2.4.6 Others 2.4.6.1 Outlook for Other Diagnostics
- Industry Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research …
… potential new uses and indications. In this way, New Rhein limits science-based risk and concentrates on development and execution. Prior investments have included medicines for Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics . New Rhein’s partners, associates, and advisors are knowledgeable former industry executives with solid track records of operational, investment, and transactional experience. New Rhein combines significant deal-making expertise with deep operating experience, allowing it …
Biocept (NASDAQ:BIOC) Stock Rating Upgraded by Zacks Investment Research | 9/13/2020
… NASDAQ:BIOC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for …
… Get Acadia Healthcare Company Inc alerts: Biocept (NASDAQ:BIOC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for …
… cells 2.0.2 Adaptive immune system 2.0.2.1 Lymphocytes 2.0.2.2 Killer T cells 2.0.2.3 Helper T cells 2.0.2.4 Gamma delta T cells 2.0.2.5 B lymphocytes and antibodies 2.0.3 Tumor immunology - The immune surveillance system 2.1 Immuno Oncology Diagnostics 2.1.1 Checkpoint Assays 2.1.1.1 Outlook for Checkpoint Assays 2.1.2 Cytokine Assays 2.1.2.1 Outlook for Cytokine Assays 2.1.3 Genomic Germline 2.1.3.1 Outlook for Genomic Germline 2.1.4 Genomic Tumour 2.1.4.1 Outlook for Genomic Tumour 2.1.5 Tumor …
… cells 2.0.2 Adaptive immune system 2.0.2.1 Lymphocytes 2.0.2.2 Killer T cells 2.0.2.3 Helper T cells 2.0.2.4 Gamma delta T cells 2.0.2.5 B lymphocytes and antibodies 2.0.3 Tumor immunology - The immune surveillance system 2.1 Immuno Oncology Diagnostics 2.1.1 Checkpoint Assays 2.1.1.1 Outlook for Checkpoint Assays 2.1.2 Cytokine Assays 2.1.2.1 Outlook for Cytokine Assays 2.1.3 Genomic Germline 2.1.3.1 Outlook for Genomic Germline 2.1.4 Genomic Tumour 2.1.4.1 Outlook for Genomic Tumour 2.1.5 Tumor …
… cells 2.0.2 Adaptive immune system 2.0.2.1 Lymphocytes 2.0.2.2 Killer T cells 2.0.2.3 Helper T cells 2.0.2.4 Gamma delta T cells 2.0.2.5 B lymphocytes and antibodies 2.0.3 Tumor immunology - The immune surveillance system 2.1 Immuno Oncology Diagnostics 2.1.1 Checkpoint Assays 2.1.1.1 Outlook for Checkpoint Assays 2.1.2 Cytokine Assays 2.1.2.1 Outlook for Cytokine Assays 2.1.3 Genomic Germline 2.1.3.1 Outlook for Genomic Germline 2.1.4 Genomic Tumour 2.1.4.1 Outlook for Genomic Tumour 2.1.5 Tumor …
… Systems Opportunities Emerging Economies Adoption of AI and Analytics in Diagnostics Imaging Use of Blockchain Contract-based Solutions Segments Covered The Global Diagnostics Imaging Market is segmented based on Product, Application, and End User. Oncology diagnostics imaging accounts for the largest market share due to the increasing prevalence of the diseases. MRI systems hold the largest market share of the Global Diagnostics Imaging Market. The growth of the segment is …
The “Global Diagnostics Imaging Market by Product, Application, End Users, Geography and the Impact of COVID-19 (2020-2025)” report has been added to ResearchAndMarkets.com’s offering. The Global Diagnostics Imaging Market is expected to grow from USD 26.3 billion in 2019 to USD 36.47 billion at a CAGR of 5.6%. Growth of the market is attributed to increasing demand for early diagnosis and increasing scope of clinical applications, rapidly increasing geriatric …
The “Global Diagnostics Imaging Market by Product, Application, End Users, Geography and the Impact of COVID-19 (2020-2025)” report has been added to ResearchAndMarkets.com’s offering. The Global Diagnostics Imaging Market is expected to grow from USD 26.3 billion in 2019 to USD 36.47 billion at a CAGR of 5.6%. Growth of the market is attributed to increasing demand for early diagnosis and increasing scope of clinical applications, rapidly increasing geriatric …
The “Global Diagnostics Imaging Market by Product, Application, End Users, Geography and the Impact of COVID-19 (2020-2025)” report has been added to ResearchAndMarkets.com’s offering. The Global Diagnostics Imaging Market is expected to grow from USD 26.3 billion in 2019 to USD 36.47 billion at a CAGR of 5.6%. Growth of the market is attributed to increasing demand for early diagnosis and increasing scope of clinical applications, rapidly increasing geriatric …
Dublin, Aug. 27, 2020 (GLOBE NEWSWIRE) – The “Immuno-Oncology Diagnostics: The Race for Biomarkers - Market Forecasts for Immuno-Oncology Diagnostics - With Executive and Consultant Guides and including Customized Forecasting and Analysis (2019 to 2023)” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. This is a complex area but this report will bring the entire management …
Equipment Leasing Companies Other Medical Imaging Technologies for Oncology Diagnostics Market Report: -Comprehensive assessment of all opportunities and risk in the Medical Imaging Technologies for Oncology Diagnostics market. – Medical Imaging Technologies for Oncology Diagnostics Medical Imaging Technologies for Oncology Diagnostics market-leading players. -Conclusive study about the growth plot of Medical Imaging Technologies for Oncology Diagnostics market for forthcoming years. -In-depth understanding of Medical Imaging Technologies for Oncology Diagnostics …
Zacks Investment Research lowered shares of Biocept (NASDAQ:BIOC) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test …
Global DNA Diagnostics/Testing Market Size, Status and Forecast 2020-2026 | 8/21/2020
… and forecast for the period 2015-2026. The key players covered in this study - Abbott Laboratories Market segment by Type, the product can be split into - PCR Based Diagnostics Market segment by Application, split into - Oncology Diagnostics & Histopathology - Pharmacogenomics Diagnostic Testing & Drug Metabolism Market segment by Regions/Countries, this report covers - North America 1.3 Players Covered: Ranking by DNA Diagnostics/Testing Revenue 1.4 Market by Type 1.4.1 Global DNA Diagnostics/Testing …
Deep Learning Applications in the Biosciences | 8/20/2020
Free 300 GB with Full DSL-Broadband Speed! Oncology diagnostics and treatment is a rapidly changing field of medicine with new advancements announced almost daily. The number of diagnostic tests to select treatments based on a patient’s unique genetic mutations and tumor pathology characteristics has grown, as have the number of therapies available. These therapies can be matched to a patient’s likelihood to respond to treatment based on the results …
Medicare
The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer … 1.5 U.S. Medical Market and laboratory Testing - Perspective 1.5.1 U.S. Medicare Expenditures for Laboratory Testing
- Immunotherapy - Guide to Immune Technologies
- The Immune System 2.1 Innate immune system 2.1.1 Surface barriers 2.1.2 Inflammation 2.1.3 …
DUBLIN- The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in … 1.5 U.S. Medical Market and laboratory Testing - Perspective 1.5.1 U.S. Medicare Expenditures for Laboratory Testing
- Immunotherapy - Guide to Immune Technologies
- The Immune System 2.1 Innate immune system 2.1.1 Surface barriers 2.1.2 Inflammation 2.1.3 …
Genomics
The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. This is a complex area but this readable report will bring the entire management team up to speed, on both the technology …
DUBLIN- The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. This is a complex area but this readable report will bring the entire management team up to speed, on both the …
Cancer Therapy
The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. This is a complex area but this readable report will bring the entire management team up to speed, on both the technology …
DUBLIN- The “The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024ec” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. This is a complex area but this readable report will bring the entire management team up to speed, on both the …
Personal Genome Diagnostics
BALTIMORE–(BUSINESS WIRE)–Jan 8, 2020– Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Mayo Clinic to enhance the development of clinical diagnostic solutions for oncology. Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications. The two organizations have a shared vision for advancing the capabilities of oncology diagnostics …
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Seq Product Qiagen, Freenome Partner to Improve Companion Diagnostic Development Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio Bristol- Myers Squibb and Illumina to Develop …
Clinical Diagnostics
Viracor Eurofins Expands Its Clinical Diagnostic Footprint to Oncology | Yahoo News | 12/11/2019
Viracor Eurofins (Viracor), proudly announces the addition of span class=”xn-person” Karina Eterovic /span , PhD, as the Director of Research & Development for Oncology Diagnostics for Eurofins U.S. Clinical Diagnostics group. Dr. Eterovic will lead the development and growth of oncology clinical diagnostic solutions to benefit our healthcare clients and their patients.” data-reactid=”12” LEE’S SUMMIT, Mo. , Dec. 11, 2019 /PRNewswire/ – Viracor Eurofins (Viracor), proudly announces the addition of …
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Genetics/Myriad RBM Nanostring Natera Neogenomics New Oncology Oncocyte Ortho Clinical Diagnostics Perkin Elmer Personal Genome Diagnostics Pfizer Promega Protagen Diagnostics Qiagen Quanterix Rarecells SAS Roche Diagnostics Siemens Silicon Biosystems SkylineDx SRI International Sysmex Thermo …
Diagnostic Tests
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 | PR Newswire | 11/14/2019
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 News provided by Nov 14, 2019, 08:15 ET Share this article DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market … for Triple-Negative Breast Cancer Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Tumor Mutational Burden as Predictor of Immunotherapy Success Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda Abcam Acquires Calico …
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Breast Cancer Icon Acquires MolecularMD Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca Tumor Mutational Burden as Predictor of Immunotherapy Success Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda Abcam Acquires Calico …
Molecular Diagnostics
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Bio-Rad Bio-Techne Bristol- Myers Squibb Cancer Genetics Caris Molecular Diagnostics CellMax Life Charles River Laboratories Chronix Biomedical Circulogene Clearbridge BioMedics Clinical Genomics Cynvenio Cytolumina Technologies Corp. CytoTrack Dako (Agilent) Diagnologix LLC Epic Sciences …
Dublin, The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has been added to ResearchAndMarkets.com’s … Bio-Rad Bio-Techne Bristol-Myers Squibb Cancer Genetics Caris Molecular Diagnostics CellMax Life Charles River Laboratories Chronix Biomedical Circulogene Clearbridge BioMedics Clinical Genomics Cynvenio Cytolumina Technologies Corp. CytoTrack Dako (Agilent) Diagnologix LLC Epic Sciences …
Cancer Diagnostics
PALM BEACH GARDENS, Fla.–( BUSINESS WIRE )– Aurora Diagnostics , the nation’s largest independent integrated anatomic pathology and oncology diagnostics practice, is celebrating 2017 achievements that include five acquisitions of high quality pathology practices and an important … organization with national scale that values, preserves, and enables great cancer diagnostics and treatment in local communities across the country.” The Company’s Aurora Research Institute (ARI), which provides cancer researchers access to a national human …
… in Clinical Oncology3.4 Emerging Metabolomic Profiling Assays May Facilitate Enhanced Cancer Diagnosis and Prognosis 4. Emerging Innovation Landscape 4.1 Redefining Oncology Diagnostics Through Comprehensive Biomarkers Assays4.2 Proteomic Markers for Precision Oncology Applications4.3 Recent Advances in … Market Potential and Intellectual Property 6.1 Oncology Biomarkers Impact Global Cancer Diagnostics Market6.2 North America Leads the Global Oncology Biomarkers Market6.3 Lung and Breast Cancer Biomarkers Present Largest Global Market Opportunities6.4 Defining Patent Research Scope …
Illumina
… North American accounted for the maximum revenue share owing to the presence of integrated platform base in U.S. Presence of Illumina, the major player of next generation sequencing market for U.S. is another major factor … and region: NGS Application Outlook (Revenue, USD Million, 2016 - 2027) Oncology Diagnostics and Screening Screening Sporadic Cancer Inherited Cancer Companion Diagnostics Other Diagnostics Research Diagnostics Clinical Investigation Infectious Diseases Idiopathic Diseases Inherited Diseases Non-Communicable …
… Biological Industries (Israel) Bio-Rad Laboratories, Inc. (USA) Cytognomix, Inc. (Canada) CytoTest, Inc. (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Illumina, Inc. (USA) Leica Biosystems Nussloch GmbH (Germany) Oxford Gene Technology (UK) PerkinElmer, Inc. (USA … Molecular Testing Services Empire Genomics Teams Up with KromaTiD for Oncology Diagnostics CytoTest Expands Sales Team in Europe Thermo Fisher Scientific Acquires Affymetrix Agilent Inks Co-Marketing Agreement with Applied Spectral Imaging Empire Genomics Expands …
Thermo Fisher
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 | PR Newswire | 11/14/2019
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 News provided by Nov 14, 2019, 08:15 ET Share this article DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market … Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio Bristol- Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies HalioDx announces high capacity IHC …
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio Bristol- Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies HalioDx announces high capacity IHC …
Bristol-Myers Squibb
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 | PR Newswire | 11/14/2019
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 News provided by Nov 14, 2019, 08:15 ET Share this article DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has been added to ResearchAndMarkets.com’s offering. Revolution in cancer therapy to be driven by new …
Dublin, The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has been added to ResearchAndMarkets.com’s … Five Prime Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies HalioDx announces high capacity IHC multiplex technology MolecularMD to Implement Promega’s Technology NCI …
Biocept
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Apocell ARUP Laboratories Beckman Coulter Becton Dickinson Bioarray Genetics BioCartis Biocept Biodesix Inc BioFluidica BioGenex bioMrieux Bio-Rad Bio-Techne Bristol- Myers Squibb Cancer Genetics Caris Molecular Diagnostics CellMax Life Charles River Laboratories Chronix Biomedical …
Biocept secures CE IVD Marks for CEE-Sure family of products in Europe | 11/8/2019
By NS Medical Staff Writer 08 Nov 2019 The CE mark allows Biocept to commercialise the approved products across the European Union and other CE Mark geographies Image: Biocept secures CE IVD Marks for two CEE-Sure family of products. Photo: Courtesy of tomwieden from Pixabay. US-based molecular oncology diagnostics company Biocept has secured Conformité Européene (CE) IVD Marks and rolled out its CEE-Sure Blood Collection Tube and …
Merck
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 | PR Newswire | 11/14/2019
Immuno-Oncology Diagnostics: The Race for Biomarkers Market to 2024 News provided by Nov 14, 2019, 08:15 ET Share this article DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market … Mutational Burden as Predictor of Immunotherapy Success Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda Abcam Acquires Calico Biolabs Cancer Genetics and NovellusDx to Merge ApoCell Expands Immuno-Oncology Biomarker Services MRM Proteomics …
DUBLIN , Nov. 14, 2019 /PRNewswire/ – The “Immuno-Oncology Diagnostics The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Executive and Consultant Guides and including Customized Forecasting and Analysis - 2020 to 2024” report has … Mutational Burden as Predictor of Immunotherapy Success Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda Abcam Acquires Calico Biolabs Cancer Genetics and NovellusDx to Merge ApoCell Expands Immuno-Oncology Biomarker Services MRM Proteomics …
About:
Editor:
